![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Molecular Pharmacology, University of Göttingen, Göttingen, Germany
Cyclosporin A and tacrolimus are clinically important immunosuppressive drugs. They share a diabetogenic action as one of their most serious adverse effects. The underlying mechanism is unknown. Previous studies have shown that tacrolimus can inhibit insulin gene transcription at high concentrations in tumor cell lines. To study insulin gene transcription in normal, mature pancreatic islet cells, we used a novel approach in the present study. Transgenic mice that carry a human insulin promoterreporter gene were generated. The human insulin promoter directed transcription in pancreatic islets and conferred a normal, physiological glucose response to reporter gene expression in isolated islets. After stimulation with glucose, human insulin promoter-mediated gene expression was inhibited in normal, mature islet cells by both tacrolimus and cyclosporin A to a large extent (approximately 70%) and with high potency at concentrations that are known to inhibit calcineurin phosphatase activity (IC50 values of 1 and 35 nM, respectively). Furthermore, glucose stimulated calcineurin phosphatase activity in mouse pancreatic islets, further supporting the view that calcineurin phosphatase activity is an essential part of glucose signaling to the human insulin gene. The high potency of cyclosporin A and tacrolimus in normal islets suggests that inhibition of insulin gene transcription by cyclosporin A and tacrolimus is clinically important and is one mechanism of the diabetogenic effect of these immunosuppressive drugs.
Received October 10, 2002; accepted February 20, 2003.
Address correspondence to: Dr. Willhart Knepel, Department of Molecular Pharmacology, Robert-Koch-Str. 40, 37075 Göttingen, Germany. E-mail: wknepel{at}med.uni-goettingen.de
This article has been cited by other articles:
|
|
 |
|
  E. Porrini, P. Delgado, A. Alvarez, M. Cobo, L. Perez, J. M. Gonzalez-Posada, L. Hortal, R. Gallego, J. J. Garcia, M. Checa, et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1436 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Plaumann, R. Blume, S. Borchers, H. J. Steinfelder, W. Knepel, and E. Oetjen Activation of the Dual-Leucine-Zipper-Bearing Kinase and Induction of {beta}-Cell Apoptosis by the Immunosuppressive Drug Cyclosporin A Mol. Pharmacol., March 1, 2008; 73(3): 652 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hui, N. Khoury, X. Zhao, L. Balkir, E. D'Amico, A. Bullotta, E. D. Nguyen, A. Gambotto, and R. Perfetti Adenovirus-Mediated XIAP Gene Transfer Reverses the Negative Effects of Immunosuppressive Drugs on Insulin Secretion and Cell Viability of Isolated Human Islets Diabetes, February 1, 2005; 54(2): 424 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Radu, S. Fujimoto, E. Mukai, M. Takehiro, D. Shimono, K. Nabe, M. Shimodahira, R. Kominato, Y. Aramaki, Y. Nishi, et al. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E365 - E371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Robertson Islet Transplantation as a Treatment for Diabetes -- A Work in Progress N. Engl. J. Med., February 12, 2004; 350(7): 694 - 705. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
